作者: Tara Maddala , David J. Mauro , Shirin K. Ford , Drew Watson , Steven Shak
DOI:
关键词: Patient response 、 Receptor 、 Pharmacology 、 Internal medicine 、 EGFR inhibitors 、 Cancer 、 Oncology 、 Medicine
摘要: The present invention provides methods and compositions to facilitate determining whether an EGFR-expressing cancer in individual is EGFR inhibitor-responsive cancer, as well for the likelihood that a patient having will exhibit beneficial response inhibitor therapy. generally involve normalized expression level of gene product correlates with responsiveness.